C4 Therapeutics, Inc.
C4 Therapeutics, Inc. (CCCC) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · CCCC · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
1
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
C4 Therapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
CCCC insider buying and selling by quarter
CCCC insider selling · CCCC insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · CCCC ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
CCCC executive sell shares · CCCC board member insider trading · CCCC insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Jun 1, 2026 | Anderson Kenneth Carl Director | Option | 1,070 | $2K | Form 4 |
| Apr 1, 2026 | Anderson Kenneth Carl Director | Award | 4,259 | $11K | Form 4 |
| Apr 1, 2026 | GROGAN DONNA ROY Director | Award | 5,370 | $14K | Form 4 |
| Feb 13, 2026 | Boyle Scott N Chief Business Officer | Award | 200,000 | — | Form 4 |
| Feb 13, 2026 | Boyle Scott N Chief Business Officer | Option | 5,000 | — | Form 4 |
| Feb 14, 2026 | Boyle Scott N Chief Business Officer | Option | 20,950 | — | Form 4 |
| Feb 13, 2026 | Boyle Scott N Chief Business Officer | Other | 1,735 | $3K | Form 4 |
| Feb 14, 2026 | Boyle Scott N Chief Business Officer | Other | 7,269 | $14K | Form 4 |
| Feb 13, 2026 | Mahaney Paige Chief Scientific Officer | Award | 240,000 | — | Form 4 |
| Feb 14, 2026 | Mahaney Paige Chief Scientific Officer | Option | 7,050 | — | Form 4 |
| Feb 14, 2026 | Mahaney Paige Chief Scientific Officer | Other | 2,446 | $5K | Form 4 |
| Feb 13, 2026 | Schick Kelly CPO | Award | 200,000 | — | Form 4 |
| Feb 13, 2026 | Schick Kelly CPO | Option | 5,000 | — | Form 4 |
| Feb 14, 2026 | Schick Kelly CPO | Option | 20,950 | — | Form 4 |
| Feb 13, 2026 | Schick Kelly CPO | Other | 1,735 | $3K | Form 4 |
| Feb 14, 2026 | Schick Kelly CPO | Other | 7,269 | $14K | Form 4 |
| Feb 14, 2026 | Hirsch Andrew President & CEO · Director | Option | 81,725 | — | Form 4 |
| Feb 13, 2026 | Hirsch Andrew President & CEO · Director | Award | 700,000 | — | Form 4 |
| Feb 14, 2026 | Hirsch Andrew President & CEO · Director | Other | 39,154 | $74K | Form 4 |
| Feb 15, 2026 | Hirsch Andrew President & CEO · Director | Option | 20,400 | — | Form 4 |
| Feb 15, 2026 | Hirsch Andrew President & CEO · Director | Other | 9,057 | $17K | Form 4 |
| Feb 13, 2026 | REYNO LEONARD Chief Medical Officer | Award | 240,000 | — | Form 4 |
| Feb 14, 2026 | REYNO LEONARD Chief Medical Officer | Option | 30,950 | — | Form 4 |
| Feb 14, 2026 | REYNO LEONARD Chief Medical Officer | Other | 16,579 | $31K | Form 4 |
| Feb 13, 2026 | Adams Kendra CFO | Award | 240,000 | — | Form 4 |
Boyle Scott N
Chief Business Officer
Date
Feb 13
Shares
1,735
Price
$1.89
Value
$3K
Boyle Scott N
Chief Business Officer
Date
Feb 14
Shares
7,269
Price
$1.89
Value
$14K
Mahaney Paige
Chief Scientific Officer
Date
Feb 14
Shares
2,446
Price
$1.89
Value
$5K
Hirsch Andrew
President & CEO · Director
Date
Feb 14
Shares
81,725
Price
—
Value
—
Hirsch Andrew
President & CEO · Director
Date
Feb 13
Shares
700,000
Price
—
Value
—
Hirsch Andrew
President & CEO · Director
Date
Feb 14
Shares
39,154
Price
$1.89
Value
$74K
Hirsch Andrew
President & CEO · Director
Date
Feb 15
Shares
20,400
Price
—
Value
—
Hirsch Andrew
President & CEO · Director
Date
Feb 15
Shares
9,057
Price
$1.89
Value
$17K
REYNO LEONARD
Chief Medical Officer
Date
Feb 14
Shares
16,579
Price
$1.89
Value
$31K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About CCCC insider trading
CCCC insider trades
C4 Therapeutics, Inc. (CCCC) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Adams Kendra (CFO), Anderson Kenneth Carl (Director), Boyle Scott N (Chief Business Officer). Over the past 12 months, 5 insiders have filed transactions with the SEC. CCCC insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For C4 Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
CCCC insider trading · 5 questionsThe insiders of C4 Therapeutics, Inc. (CCCC) include executives and directors such as Adams Kendra (CFO), Anderson Kenneth Carl (Director), Boyle Scott N (Chief Business Officer), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026